MCID: ESN005
MIFTS: 56

Eosinophilic Gastroenteritis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastroenteritis

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 72 55 51 14 69
Eosinophilic Gastroenterocolitis 55
Gastroenteritis, Eosinophilic 72
Eosinophilic Enteropathy 69
Eosinophilic Enteritis 55
Ege 55

Characteristics:

Orphanet epidemiological data:

55
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



Summaries for Eosinophilic Gastroenteritis

MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to gastroenteritis and esophagitis, and has symptoms including eosinophilia, anemia and vomiting. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Innate Immune System and Response to elevated platelet cytosolic Ca2+. The drugs Budesonide and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and small intestine.

Wikipedia : 72 Eosinophilic gastroenteritis (EG) is a rare and heterogeneous condition characterized by patchy or... more...

Related Diseases for Eosinophilic Gastroenteritis

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 gastroenteritis 30.9 ALB CCL11 IL5 RNASE3
2 esophagitis 30.6 CCL11 IL5
3 hypereosinophilic syndrome, idiopathic 30.3 IL3 IL5
4 milk allergy 30.0 IL5 RNASE3
5 eosinophilic granuloma 29.9 EPX RNASE3
6 churg-strauss syndrome 29.8 IL5 RNASE3
7 allergic bronchopulmonary aspergillosis 29.7 EPX IL5
8 dermatitis 29.7 CCL11 IL5 RNASE3
9 esophagitis, eosinophilic, 1 29.4 CCL11 EPX IL5 RNASE3
10 thrombocytosis 29.3 CSF2 IL3
11 food allergy 29.3 ALB EPX IL5 RNASE3
12 bronchitis 28.9 ALB CCL11 IL5 RNASE3
13 allergic asthma 28.8 CCL11 EPX IL5 RNASE3
14 inflammatory bowel disease 28.7 ALB CCL11 EPX IL5
15 eosinophilic pneumonia 28.1 CCL11 CSF2 IL3 IL5 RNASE3
16 hypereosinophilic syndrome 28.0 CCL11 CSF2 EPX IL3 IL5 RNASE3
17 asthma 27.9 CCL11 CSF2 EPX IL3 IL5 RNASE3
18 eosinophilic enteropathy 11.3
19 megalencephaly-capillary malformation-polymicrogyria syndrome 10.9
20 aplastic anemia 10.9
21 exercise-induced anaphylaxis 10.9
22 paroxysmal cold hemoglobinuria 10.9
23 pemphigoid gestationis 10.3 CCL11 IL5
24 chronic meningitis 10.3 CCL11 IL5
25 duodenitis 10.3
26 angiostrongyliasis 10.3 CCL11 IL5
27 strongyloidiasis 10.3 CCL11 IL5
28 eosinophilic meningitis 10.3 CCL11 IL5
29 loeffler endocarditis 10.3 IL5 RNASE3
30 folliculitis 10.2 CCL11 IL5
31 paragonimiasis 10.2 IL5 RNASE3
32 cough variant asthma 10.2 IL5 RNASE3
33 pancreatitis 10.2
34 radiculopathy 10.2 CCL11 IL5
35 cow milk allergy 10.2 IL5 RNASE3
36 latex allergy 10.2 IL5 RNASE3
37 status asthmaticus 10.2 IL5 RNASE3
38 endotheliitis 10.2
39 sinusitis 10.2 IL5 RNASE3
40 protein-losing enteropathy 10.2
41 blepharoconjunctivitis 10.2 CCL11 RNASE3
42 cellulitis 10.2 IL5 RNASE3
43 wells syndrome 10.2 IL5 RNASE3
44 mucositis 10.1
45 parasitic helminthiasis infectious disease 10.1 IL5 RNASE3
46 filariasis 10.1 ALB IL5
47 pyloric stenosis 10.1
48 episodic pain syndrome, familial, 1 10.1
49 duodenal ulcer 10.1
50 acute pancreatitis 10.1

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

Human phenotypes related to Eosinophilic Gastroenteritis:

55 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eosinophilia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001880
2 anemia 55 31 frequent (33%) Frequent (79-30%) HP:0001903
3 vomiting 55 31 frequent (33%) Frequent (79-30%) HP:0002013
4 dysphagia 55 31 frequent (33%) Frequent (79-30%) HP:0002015
5 abdominal pain 55 31 frequent (33%) Frequent (79-30%) HP:0002027
6 steatorrhea 55 31 frequent (33%) Frequent (79-30%) HP:0002570
7 hypoalbuminemia 55 31 frequent (33%) Frequent (79-30%) HP:0003073
8 allergic rhinitis 55 31 frequent (33%) Frequent (79-30%) HP:0003193
9 elevated c-reactive protein level 55 31 frequent (33%) Frequent (79-30%) HP:0011227
10 abnormal test result 55 31 frequent (33%) Frequent (79-30%) HP:0500014
11 edema 55 31 occasional (7.5%) Occasional (29-5%) HP:0000969
12 atopic dermatitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001047
13 ascites 55 31 occasional (7.5%) Occasional (29-5%) HP:0001541
14 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
15 asthma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002099
16 protein-losing enteropathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002243
17 hematochezia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002573
18 elevated erythrocyte sedimentation rate 55 31 occasional (7.5%) Occasional (29-5%) HP:0003565
19 leukocytosis 55 Frequent (79-30%)
20 diarrhea 55 Frequent (79-30%)
21 malabsorption 55 Frequent (79-30%)
22 abnormality of the gastrointestinal tract 55 Frequent (79-30%)

Drugs & Therapeutics for Eosinophilic Gastroenteritis

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 5281004 63006
2
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
3
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1 103577-45-3 3883
4
Menthol Approved Phase 4 2216-51-5 16666
5 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Cromolyn Sodium Phase 4
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Autonomic Agents Phase 4,Phase 3,Phase 2
11 Bronchodilator Agents Phase 4,Phase 3,Phase 2
12 Dermatologic Agents Phase 4,Phase 3,Phase 2
13
Fluticasone Phase 4,Phase 3,Phase 2 80474-14-2, 90566-53-3 22833648 62924
14 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
19 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Proton pump inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Olive Nutraceutical Phase 4
24 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3
25
Montelukast Approved Phase 3,Phase 1 158966-92-8 5281040
26
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 119141-88-7 9579578 4594
27 Leukotriene Antagonists Phase 3,Phase 1
28
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
29
Infliximab Approved Phase 2 170277-31-3
30
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Losartan Approved Phase 2 114798-26-4 3961
32
Bethanechol Approved Phase 2 674-38-4 2370
33 Antibodies Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 2,Phase 1
35 Immunoglobulins Phase 2,Phase 1
36 Indoleacetic Acids Phase 2
37 Antirheumatic Agents Phase 2
38 interferons Phase 1, Phase 2
39 Neurotransmitter Agents Phase 2
40 Pharmaceutical Solutions Phase 2
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Angiotensin Receptor Antagonists Phase 2
43 Angiotensinogen Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Antihypertensive Agents Phase 2
46 Vasoconstrictor Agents Phase 2
47 mometasone furoate Phase 2
48 Cholinergic Agents Phase 2
49
Lactulose Approved Phase 1 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453

Interventional clinical trials:

(show top 50) (show all 122)

# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4 Budesonide;Fluticasone
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
5 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
6 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
7 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
8 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
9 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
10 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
11 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
12 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
13 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3 OBS;Placebo
14 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
15 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Recruiting NCT02610816 Phase 2, Phase 3 Flovent (fluticasone propionate)
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2, Phase 3 EMS Fluticasone 1;EMS Fluticasone 2;EMS Fluticasone 3
18 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
19 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
20 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
21 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
22 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
23 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
24 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
25 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
26 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
27 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
28 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
29 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
30 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
31 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
32 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
33 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
34 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
35 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
36 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
37 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
38 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03191864 Phase 2 APT-1011;Placebo
39 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Recruiting NCT01821898 Phase 2 Oral Budesonide
40 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
41 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
42 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
43 Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. Enrolling by invitation NCT02113267 Phase 2 Mometasone furoate;Placebo
44 Bethanechol for Eosinophilic Esophagitis Terminated NCT02058537 Phase 2 Bethanechol
45 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Withdrawn NCT01479231 Phase 1, Phase 2 dexlansoprazole
46 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
47 Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring Unknown status NCT01447823 Phase 1
48 Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Completed NCT01641913 Phase 1
49 Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Completed NCT01040598 Phase 1
50 Trial of Montelukast in Eosinophilic Esophagitis Completed NCT00511316 Phase 1 Montelukast/ Singulair;Placebo

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Genetic Tests for Eosinophilic Gastroenteritis

Anatomical Context for Eosinophilic Gastroenteritis

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

38
Colon, Testes, Small Intestine, T Cells, Liver, Lymph Node, Bone

Publications for Eosinophilic Gastroenteritis

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 396)
# Title Authors Year
1
A Case of Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
2
Eosinophilic gastroenteritis presenting with gastric perforation. ( 29366927 )
2018
3
Diagnosis of eosinophilic gastroenteritis is easily missed. ( 28596692 )
2017
4
Eosinophilic Ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in a Young Adult Male. ( 29255753 )
2017
5
Eosinophilic Ascites-Rarest Presentation of a Rare Disease, Eosinophilic Gastroenteritis. ( 29313586 )
2017
6
CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. ( 28497923 )
2017
7
Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28644350 )
2017
8
Eosinophilic gastroenteritis in a teenager: A rare diagnosis. ( 27283450 )
2017
9
Eosinophilic gastroenteritis presenting as upper gastrointestinal hematoma and ulcers after endoscopic biopsy: A case report and literature review. ( 28906408 )
2017
10
Post-partum eosinophilic gastroenteritis: A case report. ( 28081983 )
2017
11
Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28943560 )
2017
12
Eosinophilic gastroenteritis caused by eating hens' eggs: A case report. ( 28279648 )
2017
13
Hematemesis as Initial Presentation in a 10-Week-Old Infant with Eosinophilic Gastroenteritis. ( 28299223 )
2017
14
Eosinophilic Gastroenteritis Presenting with Red Streaking. ( 28250308 )
2017
15
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. ( 28603057 )
2017
16
Eosinophilic gastroenteritis: three clinical cases with different presentations. ( 28063615 )
2017
17
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. ( 29212311 )
2017
18
Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab. ( 27018120 )
2016
19
Lack of Knowledge and Low Readiness for Healthcare Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 27657884 )
2016
20
Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. ( 27466473 )
2016
21
Eosinophilic gastroenteritis in an 18-year-old male with prolonged nephrotic syndrome. ( 28018451 )
2016
22
Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. ( 26948075 )
2016
23
Eosinophilic Gastroenteritis: An Underdiagnosed Condition. ( 27234270 )
2016
24
Eosinophilic gastroenteritis: Approach to diagnosis and management. ( 27867684 )
2016
25
Eosinophilic gastroenteritis: A state-of-the-art review. ( 27253425 )
2016
26
Eosinophilic gastroenteritis: a challenge to diagnose and treat. ( 27613263 )
2016
27
Severe eosinophilic gastroenteritis. ( 26802190 )
2016
28
Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain. ( 27274524 )
2016
29
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency. ( 26840762 )
2016
30
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
31
Eosinophilic Gastroenteritis: Case Report and Review in Search for Diagnostic Key Points. ( 26075112 )
2015
32
Allergic Bronchopulmonary Aspergillosis Associated With Eosinophilic Gastroenteritis. ( 26727774 )
2015
33
Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. ( 25547198 )
2015
34
The management of eosinophilic gastroenteritis. ( 26027839 )
2015
35
A Case of Proton Pump Inhibitor-Resistant Multiple Gastric Ulcers Caused by Eosinophilic Gastroenteritis. ( 26272422 )
2015
36
Eosinophilic gastroenteritis due to rhus ingestion presenting with gastrointestinal hemorrhage. ( 25844348 )
2015
37
Perforated duodenal ulcer: An unusual manifestation of allergic eosinophilic gastroenteritis. ( 26640348 )
2015
38
Eosinophilic gastroenteritis after allogeneic bone marrow transplantation. ( 25913480 )
2015
39
Eosinophilic gastroenteritis mimicking as a malignant gastric ulcer with lymphadenopathy as shown by computed tomography and endoscopic ultrasound. ( 25789292 )
2015
40
Eosinophilic gastroenteritis due to egg allergy presenting as acute pancreatitis. ( 25668683 )
2015
41
Differences in Features and Course of Mucosal Type Eosinophilic Gastroenteritis between Korean Infants and Children. ( 26240491 )
2015
42
Milk-sensitive eosinophilic gastroenteritis in a 2-month-old boy. ( 26272958 )
2015
43
Obstructive eosinophilic gastroenteritis in a patient with rheumatoid arthritis. ( 26264946 )
2015
44
Eosinophilic Gastroenteritis with Ascites in a Child. ( 26388635 )
2015
45
Eosinophilic gastroenteritis: Clinical profiles and treatment outcomes, a retrospective study of 18 adult patients in a Singapore Tertiary Hospital. ( 26358020 )
2015
46
An Atypical Case of Eosinophilic Gastroenteritis Presenting as Hypovolemic Shock. ( 26078733 )
2015
47
Systematic Review: The Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic Gastroenteritis. ( 25699593 )
2015
48
A Case of Eosinophilic Gastroenteritis with Ascites. ( 26819619 )
2015
49
Proton pump inhibitor treatment decreased duodenal and esophageal eosinophilia in a case of eosinophilic gastroenteritis. ( 26344087 )
2015
50
Eosinophilic gastroenteritis and bowel obstruction. Can surgery be avoided? ( 25733047 )
2015

Variations for Eosinophilic Gastroenteritis

Expression for Eosinophilic Gastroenteritis

Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.

Pathways for Eosinophilic Gastroenteritis

Pathways related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CCL11 CSF2 EPX IL3 IL5 RNASE3
2
Show member pathways
12.95 ALB CSF2 IL3 IL5
3
Show member pathways
12.93 CCL11 CSF2 IL3 IL5
4
Show member pathways
12.24 CSF2 IL3 IL5
5
Show member pathways
12.09 CCL11 EPX IL3 IL5 RNASE3
6
Show member pathways
12.05 CSF2 IL3 IL5
7
Show member pathways
12.02 CCL11 CSF2 IL5
8
Show member pathways
11.82 CSF2 IL3 IL5
9 11.67 CSF2 IL3 IL5
10 11.57 CSF2 IL3 IL5
11 11.5 CSF2 IL5
12
Show member pathways
11.43 CSF2 IL3 IL5
13 11.36 CCL11 IL5
14 11.3 CCL11 CSF2 IL5
15 11.19 CCL11 IL5
16 11.11 CSF2 IL3 IL5
17 10.69 CCL11 CSF2 IL3 IL5
18 10.68 CCL11 CSF2 IL3 IL5
19 10.28 CSF2 IL3 IL5

GO Terms for Eosinophilic Gastroenteritis

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB CCL11 CSF2 EPX IL3 IL5
2 extracellular space GO:0005615 9.17 ALB CCL11 CSF2 EPX IL3 IL5

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.5 CSF2 IL3 IL5
2 immune response GO:0006955 9.46 CCL11 CSF2 IL3 IL5
3 cellular oxidant detoxification GO:0098869 9.43 ALB EPX
4 peptidyl-tyrosine phosphorylation GO:0018108 9.43 CSF2 IL3 IL5
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.4 CSF2 IL3
6 positive regulation of DNA replication GO:0045740 9.37 CSF2 IL3
7 positive regulation of podosome assembly GO:0071803 8.96 CSF2 IL5
8 regulation of receptor activity GO:0010469 8.92 CCL11 CSF2 IL3 IL5

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 CSF2 IL3 IL5
2 protein tyrosine kinase activity GO:0004713 9.33 CSF2 IL3 IL5
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 CSF2 IL3 IL5
4 cytokine activity GO:0005125 8.92 CCL11 CSF2 IL3 IL5

Sources for Eosinophilic Gastroenteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....